JAMA Internal Medicine
EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, NOVEMBER 1, 2021
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2021.6352?guestAccessKey=f6fff3e2-d1bf-4380-955b-4320910dbcaf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110121
What The Study Did: Resarchers compared post-Ad26.COV2.S (Johnson & Johnson/Janssen) vaccination cerebral venous sinus thrombosis (CVST, a blood clot in the brain) rates with prepandemic rates to estimate postvaccination CVST risk. The rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19.
Authors: Aneel A. Ashrani, M.D., M.S., of the Mayo Clinic in Rochester, Minnesota, is the corresponding author.
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.